跳至主要内容
临床试验/NCT00998751
NCT00998751已完成2 期

Phase 2 Study of Oral AB1010 in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

AB Science1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2005年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
Objective response rate according to Response Evaluation Criteria In Solid Tumors (RECIST)

研究概览

简要总结

The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or Female patients, age >18
  • Life expectancy > 6 months
  • Histological proven, metastatic, or locally advanced and non-operable, non- pre-treated GIST.
  • Patients having never received any tyrosine kinase inhibitor, including as adjuvant therapy
  • C-Kit (CD117) positive tumors detected immuno-histochemically
  • Measurable tumor lesions with longest diameter >20 mm using conventional techniques or >10 mm with spiral CT scan

排除标准

  • Documented allergy to the similar drug of AB1010
  • Inadequate organ function
  • Patients with a history of any other malignancy

研究组 & 干预措施

masitinib (AB1010)

Experimental

oral masitinib 7.5 mg/kg/day

干预措施: oral masitinib (Drug)

结局指标

主要结局

Objective response rate according to Response Evaluation Criteria In Solid Tumors (RECIST)

时间窗: 2 months

次要结局

  • Progression Free Survival(until disease progression)

研究者

发起方
AB Science
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验